Skip to main content
. 2019 May 24;38(2):468–477. doi: 10.1007/s10637-019-00787-3

Table 2.

Treatment-related adverse events reported in two or more patients during Stage 1

TRAE, n Navoximod 400 mg (N = 3) Navoximod 600 mg (N = 4) Navoximod 1000 mg (N = 3) Total (N = 10)
Any, n
  All grades 1 2 3 6
  Grade ≥ 3 1 1 0 2
Chromaturia, n
  All grades 0 2 3 5
  Grade ≥ 3 0 0 0 0
Maculopapular rash, n
  All grades 1 0 1 2
  Grade ≥ 3 1 0 0 1

TRAE treatment-related adverse event